Long‐Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open‐Label Extension Study

OBJECTIVE: To investigate long‐term safety and tolerability of anifrolumab, a human monoclonal antibody to the type I interferon (IFN) receptor subunit 1, in patients with moderate‐to‐severe systemic lupus erythematosus (SLE). METHODS: This 3‐year, multinational, open‐label extension study included...

Descripción completa

Detalles Bibliográficos
Autores principales: Chatham, W. Winn, Furie, Richard, Saxena, Amit, Brohawn, Philip, Schwetje, Erik, Abreu, Gabriel, Tummala, Raj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Systemic Lupus Erythematosus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252065/
https://www.ncbi.nlm.nih.gov/pubmed/33225631
http://dx.doi.org/10.1002/art.41598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252065/
https://www.ncbi.nlm.nih.gov/pubmed/33225631
http://dx.doi.org/10.1002/art.41598

Ejemplares similares